BPC-157
Body Protection Compound 157
BPC-157 is a synthetic peptide whose promoted regenerative effects come almost entirely from animal and laboratory research. Reliable human efficacy and safety data are lacking.
Peptipedia explains research and prescribing information. It does not replace medical advice and is not an invitation to use a substance.
Identity not confirmed
The name may refer to different substance or product forms.
BPC-157 denotes a synthetic pentadecapeptide. Free base, acetate and other marketed forms are not interchangeable without product specifications.
Research areas
Evidence matrix
- Molecular identity
- Partially clarified
BPC-157 denotes a synthetic pentadecapeptide. Free base, acetate and other marketed forms are not interchangeable without product specifications.
- Human research
- Very limited
- Replication
- No independent replication
- Clinical endpoints
- No clinical endpoints
- Safety
- Not adequately studied
- Approval
- No documented approval
The dimensions are presented separately and are not combined into an overall score.
Evidence base
Mainly preclinical research; small human pilots cannot establish safety.
- Safety of Intravenous Infusion of BPC157 in Humans: A Pilot StudyHuman study2025
U.S. National Library of Medicine (PubMed)
Accessed:
- FDA: Safety risks associated with BPC-157 in compoundingRegulatory source2024
U.S. Food and Drug Administration
Accessed:
- BPC 157 accelerates healing of transected rat Achilles tendon and stimulates tendocyte growthAnimal study2003
U.S. National Library of Medicine (PubMed)
Accessed:
Research gaps
- ·The uncontrolled 2025 pilot includes only two previously exposed participants.
- ·No robust controlled human efficacy trials
- ·No adequately characterized clinical pharmacokinetics
- ·Uncertain long-term safety and product quality
Mechanism
Animal and cell models have reported effects on tendon cells, collagen organization and blood-vessel formation. These findings do not establish a mechanism or benefit in humans.
- BPC 157 accelerates healing of transected rat Achilles tendon and stimulates tendocyte growthAnimal study2003
U.S. National Library of Medicine (PubMed)
Accessed:
Study protocols
No sufficiently supported, exactly citable study protocols are available.
Calculator
Arithmetic based only on your entries. Not a dose or use recommendation.
Reported adverse effects
- ·Immunogenicity and product impurities remain unresolved; the two-person infusion study does not exclude risks.
Contraindications and warnings
- ·Contraindications cannot be determined reliably because adequate human data are unavailable.
Interactions
- ·Interactions for the research or product forms described here have not been adequately studied.
Research gaps
- ·The uncontrolled 2025 pilot includes only two previously exposed participants.
- ·No robust controlled human efficacy trials
- ·No adequately characterized clinical pharmacokinetics
- ·Uncertain long-term safety and product quality
- Safety of Intravenous Infusion of BPC157 in Humans: A Pilot StudyHuman study2025
U.S. National Library of Medicine (PubMed)
Accessed:
- FDA: Safety risks associated with BPC-157 in compoundingRegulatory source2024
U.S. Food and Drug Administration
Accessed:
Sources
Sources checked: · Version 2
- Safety of Intravenous Infusion of BPC157 in Humans: A Pilot StudyHuman study2025
U.S. National Library of Medicine (PubMed)
Accessed:
- FDA: Safety risks associated with BPC-157 in compoundingRegulatory source2024
U.S. Food and Drug Administration
Accessed:
- BPC 157 accelerates healing of transected rat Achilles tendon and stimulates tendocyte growthAnimal study2003
U.S. National Library of Medicine (PubMed)
Accessed: